This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Senan, S. Articles by Smit, E. F. Search for Related Content PubMed PubMed Citation Articles by Senan, S. Articles by Smit, E. F.

Radiation Oncology

Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy

Departments of Radiation Oncology and Pulmonology, VU University Medical Center, Amsterdam, The Netherlands

Key Words. Tumor angiogenesis • Radiotherapy • Antiangiogenic therapy • Hypoxia • Clinical trials

Correspondence: Suresh Senan, MRCP, FRCR, Ph.D., Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands. Telephone: 31204440414; Fax: 31204440410; e-mail: s.senan{at}vumc.nl

Clinical trials showing longer survival when chemotherapy is combined with antiangiogenic agents (AAs) have led to growing interest in designing combined modality protocols that exploit abnormalities in tumor vasculature. Approved agents include bevacizumab, a recombinant monoclonal antibody that binds to vascular endothelial growth factor, and two small molecule multitargeted tyrosine kinase inhibitors of angiogenesis (SU11248 and BAY-43–9006) that have been approved for therapy of renal cancer. Targeting tumor vasculature has a strong biological rationale in radiation therapy, and preclinical studies consistently show an increase in radiosensitization with combined treatment. Preclinical studies indicate that excessive damage to tumor vasculature can result in radioresistance in some situations, and early clinical data suggest that treatment sequencing may be important when combining AAs with radiation. Radiation itself appears to antagonize any hypoxia that can be induced by long-term administration of AAs. The optimal biological doses of AAs with radiotherapy are unknown, and surrogate markers of efficacy remain to be validated. Early clinical trials should therefore include studies designed to identify mechanisms of interaction and increases in tumor hypoxia. This review highlights preclinical and early clinical data that are relevant for clinical trial design. Optimal radiation planning and delivery is required to minimize the volume of irradiated normal organs and to establish safe dose-volume parameters for phase II–III clinical trials.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				H. S. BACHMANN, H. RUBBEN, K. W. SCHMID, W. SIFFERT, and K. RIEMANN DNA Repair Gene XRCC1 Polymorphisms and Outcome of Renal Cell Carcinoma in Caucasian Patients Anticancer Res, December 1, 2009; 29(12): 5131 - 5135. [Abstract] [Full Text] [PDF]

				A. Saleem and P. M. Price Early Tumor Drug Pharmacokinetics Is Influenced by Tumor Perfusion but not Plasma Drug Exposure Clin. Cancer Res., December 15, 2008; 14(24): 8184 - 8190. [Abstract] [Full Text] [PDF]